3 completed, 2 recruiting, 1 terminated, 1 unknown. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
Follow serabelisib: new trials by email Literature Review of serabelisib trials Research Report on serabelisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Faeth Therapeutics | 32 | 2026-04-22 | 2026-07-02 |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Sapanisertib, Serabelisib, Paclitaxel - Endometrial Cancer | Phase 2 | Recruiting | Faeth Therapeutics | 40 | 2024-12-12 | 2025-12-24 |
| A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Serabelisib, Canagliflozin 300mg - Breast Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Unknown | Petra Pharma | 60 | 2020-09-01 | 2020-05-21 |
| TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel - Triple Negative Breast Cancer | Phase 2 | Completed | Joyce O'Shaughnessy | 12 | 2017-07-18 | 2023-08-07 |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Everolimus, MLN0128, MLN1117 - Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 96 | 2016-06-30 | 2021-11-19 |
| A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer Paclitaxel, Sapanisertib, MLN1117 - Endometrial Neoplasms | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 241 | 2016-04-01 | 2021-11-24 |
| Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer Docetaxel, TAK-117 - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 14 | 2015-06-03 | 2018-02-07 |
Endometrial Neoplasms (3) · Breast Neoplasms (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Carcinoma, Endometrioid (1) · Carcinoma, Non-Small-Cell Lung (1) · Clear-cell metastatic renal cell carcinoma (1) · Colonic Neoplasms (1) · Genital Diseases (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Millennium Pharmaceuticals, Inc. (3) · Faeth Therapeutics (2) · Joyce O'Shaughnessy (1) · Petra Pharma (1)
United States (6) · Canada (3) · Italy (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Norway (1) · Poland (1)
Albert Yu, MD (1) · Joyce O'Shaughnessy, MD (1)
2014 (2), 2015 (1)